Pharmaceuticals produced in Russia are not safe. This situation may be confirmed by the analysis of top 20 pharmacological companies, 19 of which are based in Europe, said Burul Makenbayeva, coordinator of the non-governmental coalition for the transparency of drug supply.
She presented an overview of open literature on October 22 on what may affect the pharmaceutical market of Kyrgyzstan upon its accession to the Customs Union. The overview, she said, causes certain warnings.
In line with the collected data, amendments to the legislation of Kyrgyzstan are made too quickly without the necessary expertise, the expert said.
Makenbayeva also expressed concerns over planned creation of a common market of medicines in 2016.
“Health systems of the countries of the Customs Union differ. Policies of evidence-based medicine and rational use of drugs are at various stages of development,” she noticed.
Original url : www.akipress.com